PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to validate the efficacy and safety of anti-PD-1 in
combination with neoadjuvant chemotherapy in women with advanced ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University